GlassScriptPhysician profile
Alejandro Llanos Chea
NPI 1942564380
$1,763.42
in general payments reported to CMS, 2019-2025
13 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2022: $22.82 · 2023: $495 · 2024: $647 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $409.67 | 2022-2025 | Gattex, Eohilia, Vpriv |
| Medtronic, INC. | $334.61 | 2023-2024 | Endoflip |
| Regeneron Healthcare Solutions, INC. | $294.48 | 2023-2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $167.56 | 2023-2025 | Livmarli, Chenodal, Cholbam |
| Janssen Biotech, INC. | $153.11 | 2023-2024 | Stelara |
| Abbvie INC. | $119.44 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $84.24 | 2023-2025 | Bylvay |
| Alcresta Therapeutics, INC. | $49.64 | 2024-2025 | Relizorb |
| Eton Pharmaceuticals, INC. | $42.58 | 2025 | Carglumic Acid, Galzin, Nitisinone |
| Pharming Healthcare, INC. | $34.32 | 2023-2024 | Ruconest |
| Acadia Pharmaceuticals INC | $26.55 | 2023 | Daybue |
| Aimmune Therapeutics, INC. | $24.50 | 2025 | Zenpep |
| Qol Medical, LLC | $22.72 | 2023 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Llanos Chea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.